Patents by Inventor Francis Blanche

Francis Blanche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6649394
    Abstract: A novel topoisomerase IV, nucleotide sequences coding for said enzyme, corresponding vectors, and the use of said enzyme for screening biologically active materials.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: November 18, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Béatrice Cameron, Joël Crouzet, Alain Famechon, Lucia Ferrero
  • Publication number: 20030186268
    Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.
    Type: Application
    Filed: April 7, 2003
    Publication date: October 2, 2003
    Inventors: Joel Crouzet, Daniel Scherman, Pierre Wils, Francis Blanche, Beatrice Cameron
  • Publication number: 20030170710
    Abstract: The invention concerns a novel method for purifying and quantifying viral particles. More particularly, the invention concerns a method for purifying and quantifying adenovirus by ion-exchange chromatography. The invention also concerns a method for identifying different adenovirus serotypes.
    Type: Application
    Filed: February 25, 2003
    Publication date: September 11, 2003
    Applicant: Aventis Pharma S.A.
    Inventors: Francis Blanche, Anne Barbot, Beatrice Cameron
  • Publication number: 20030165876
    Abstract: The present invention relates to novel target double-stranded DNA sequences capable of interacting with a third strand and of forming a stable triple helix. The present invention also relates to a process for purifying a double-stranded DNA molecule, according to which a solution containing said DNA molecule is brought into contact with a third DNA strand capable of forming, by hybridization, a triple helix structure with a target double-stranded DNA sequence carried by said DNA molecule.
    Type: Application
    Filed: March 25, 2002
    Publication date: September 4, 2003
    Inventors: Francis Blanche, Beatrice Cameron
  • Publication number: 20030143730
    Abstract: The invention concerns a method for producing recombinant adenovirus by which viral DNA is introduced in a packaging cell culture and the viruses produced are harvested after liberation in the supernatant. The invention also concerns the viruses produced and their use.
    Type: Application
    Filed: October 10, 2002
    Publication date: July 31, 2003
    Applicant: Aventis Pharma S.A.
    Inventors: Francis Blanche, Jean-Marc Guillaume
  • Patent number: 6537793
    Abstract: The invention concerns a novel method for purifying and quantifying viral particles. More particularly, the invention concerns a method for purifying and quantifying adenovirus by ion-exchange chromatography. The invention also concerns a method for identifying different adenovirus serotypes.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: March 25, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Anne Barbot, Beatrice Cameron
  • Publication number: 20030032092
    Abstract: The invention provides double-stranded circular DNA molecules having one or more genes of interest, but lacking an origin of replication and a selectable marker, and methods for making such molecules.
    Type: Application
    Filed: October 19, 2001
    Publication date: February 13, 2003
    Inventors: Francis Blanche, Beatrice Cameron
  • Patent number: 6518062
    Abstract: Enzyme combinations useful for destroying cells, particularly proliferative cells, are disclosed. In particular, a combination of the following enzymes has been found to enhance the toxicity of nucleoside analogues to proliferating cells: an enzyme that phosphorylates the non-toxic nucleoside analogue to generate a monophosphate analogue, an enzyme that phosphorylates the monophosphate analogue to generate a diphosphate analogue and an enzyme that phosphorylates the diphosphate analogue to generate a toxic triphosphate analogue. Vectors enabling the intracellular expression and transfer of the enzyme combinations, as well as their therapeutic use, particularly in anti-cancer gene therapy, are also disclosed.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: February 11, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Béatrice Cameron, Michel Couder, Joël Crouzet
  • Patent number: 6485958
    Abstract: The invention concerns a method for producing recombinant adenovirus by which viral DNA is introduced in a packaging cell culture and the viruses produced are harvested after liberation in the supernatant. The invention also concerns the viruses produced and their use.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: November 26, 2002
    Inventors: Francis Blanche, Jean-Marc Guillaume
  • Publication number: 20020142947
    Abstract: Novel group B streptogramine-like compounds of general formula (I), and a method for preparing streptogramines by muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines, are disclosed. Novel nucleotide sequences involved in the biosynthesis of said precursors, and their uses, are also disclosed.
    Type: Application
    Filed: November 15, 2001
    Publication date: October 3, 2002
    Applicant: Aventis Pharma, S.A.
    Inventors: Veronique Blanc, Denis Thibaut, Nathalie Bamas-Jacques, Francis Blanche, Joel Crouzet, Jean-Claude Barriere, Laurent Debussche, Alain Famechon, Jean-Marc Paris, Gilles Dutruc-Rosset
  • Publication number: 20020102247
    Abstract: The present invention relates to a nucleic acid sequence characterized in that it is derived from the wild nucleic acid sequence coding for a thymidine kinase, said nucleic acid sequence having at least one mutation in the region corresponding to the ATP binding site and conveniently a second mutation in the N-terminal region and/or C-terminal region. It also relates to variants of the wild thymidine kinase and their use in genic therapy.
    Type: Application
    Filed: December 12, 2000
    Publication date: August 1, 2002
    Inventors: Joel Crouzet, Francis Blanche, Michel Couder, Beatrice Cameron
  • Publication number: 20020061592
    Abstract: Liquid or frozen compositions containing adenoviral particles, comprising a buffer solution capable of maintaining the pH of the medium at slightly alkaline values, supplemented with glycerol and without addition of divalent metal cations or of alkali metal cations.
    Type: Application
    Filed: October 5, 2001
    Publication date: May 23, 2002
    Inventors: Francis Blanche, Shian-Jiun Shih
  • Publication number: 20020037565
    Abstract: The invention concerns a novel method for purifying and quantifying viral particles. More particularly, the invention concerns a method for purifying and quantifying adenovirus by ion-exchange chromatography. The invention also concerns a method for identifying different adenovirus serotypes.
    Type: Application
    Filed: June 14, 2001
    Publication date: March 28, 2002
    Inventors: Francis Blanche, Anne Barbot, Beatrice Cameron
  • Publication number: 20020028497
    Abstract: The invention concerns a method for producing recombinant adenovirus by which viral DNA is introduced in a packaging cell culture and the viruses produced are harvested after liberation in the supernatant. The invention also concerns the viruses produced and their use.
    Type: Application
    Filed: December 16, 1998
    Publication date: March 7, 2002
    Inventors: FRANCIS BLANCHE, JEAN-MARC GUILLAUME
  • Patent number: 6352839
    Abstract: The invention provides a method for preparing streptogramins using genetically-modified microorganisms to influence the biosynthesis of at least one of the precursors of the group B streptogramins. Cultures of the genetically-modified microorganisms are supplemented with a least one precursor that is different from the streptogramin precursor whose biosynthesis is altered and the streptogramins produced are recovered.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: March 5, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Véronique Blanc, Denis Thibaut, Nathalie Bamas-Jacques, Francis Blanche, Joël Crouzet, Jean-Claude Barriere, Laurent Debussche, Alain Famechon, Jean-Marc Paris, Gilles Dutruc-Rosset
  • Patent number: 6319672
    Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: November 20, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Joël Crouzet, Daniel Scherman, Pierre Wils, Françis Blanche, Béatrice Cameron
  • Patent number: 6207150
    Abstract: The present invention relates to a nucleic acid sequence characterized in that it is derived from the wild nucleic acid sequence coding for a thymidine kinase, said nucleic acid sequence having at least one mutation in the region corresponding to the ATP binding site and conveniently a second mutation in the N-terminal region and/or C-terminal region. It also relates to variants of the wild thymidine kinase and their use in genic therapy.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 27, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Joël Crouzet, Francis Blanche, Michel Couder, Béatrice Cameron
  • Patent number: 6171846
    Abstract: The invention concerns mutant microorganisms blocked in a step of Streptogramin biosynthesis and methods for preparing cells blocked in a step of Streptogramin biosynthesis.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: January 9, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Veronique Blanc, Francis Blanche, Joel Crouzet, Nathalie Jacques, Patricia LaCroix, Denis Thibaut, Monique Zagorec, Laurent DeBussche, Valerie De Crecy-Lagard
  • Patent number: 6156545
    Abstract: The present invention relates to a biosynthetic process for preparing cobalamines. More precisely, it relates to a process for amplifying the production of cobalamines and, more specifically, of coenzyme B.sub.12 by means of recombinant DNA techniques and/or by means of adding a novel cobalamine precursor.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: December 5, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Francis Blanche, Beatrice Cameron, Joel Crouzet, Laurent Debussche, Denis Thibaut, Elisabeth Remy
  • Patent number: 6153597
    Abstract: A pharmaceutical composition useful for nucleic acid transfection is disclosed. The composition contains, in addition to a nucleic acid and at least one transfection agent, at least one compound that combines DNA binding properties with a nuclear DNA vectorisation capability, and preferably belongs to the HMG ("High mobility group") protein family. The use of said composition for in vitro, ex vivo and/or in vivo nucleic acid transfer is also disclosed.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: November 28, 2000
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Beatrice Cameron, Joel Crouzet, Vincent Thuillier